North America genetic testing market is expected to reach USD 25,045,918.59 thousand by 2031 from USD 7,381,854.06 thousand in 2023 with growing at a CAGR of 16.8% during the forecast period of 2024 to 2031. Market Segmentation North America Genetic Testing Market, By Type (Carrier Testing, Diagnostic Testing, New Born Screening, Predictive and Presymptomatic Testing, and Other Types), Technology (DNA sequencing, Polymerase Chain Reaction, Microarrays, Whole Genome Sequencing, Fluorescence In Situ Hybridization (FISH), and Others), Diseases (Rare Genetic Disorder, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntington’s Disease, Fragile X Syndrome, and Other Diseases), End User (Hospitals, Clinics, Diagnostic Centers, Private Clinics, Laboratory Service Providers, and Private Laboratories), By Country (U.S., Canada, and Mexico) - Industry Trends and Forecast to 2031 Overview of Global Genetic Testing Market Dynamics Driver • Growing prevalence of genetic disorders Restrain • High cost of genetic testing Opportunity • Strategic initiatives by the key market player Market Players Some of the key market players for North America genetic testing market are: • Thermo Fisher Scientific Inc. • Invitae Corporation • Bio-Rad Laboratories, Inc. • PerkinElmer Inc. • Illumina, Inc. • QIAGEN • F. Hoffmann-La Roche Ltd. • Fulgent Genetics • Myriad Genetics, Inc. • Abbott • Eurofins Scientific • Sorenson Genomics • BIO-HELIX • Biocartis • Cepheid (A subsidiary of Danaher) • PacBio • ELITechGroup • Genes2Me • Eugene Labs • Otogenetics • Mapmygenome • MedGenome • BioReference • Natera, Inc.

1 INTRODUCTION 66 1.1 OBJECTIVES OF THE STUDY 66 1.2 MARKET DEFINITION 66 1.3 OVERVIEW OF THE NORTH AMERICA GENETIC TESTING MARKET 66 1.4 LIMITATIONS 68 1.5 MARKETS COVERED 68 2 MARKET SEGMENTATION 71 2.1 MARKETS COVERED 71 2.2 GEOGRAPHICAL SCOPE 72 2.3 YEARS CONSIDERED FOR THE STUDY 73 2.4 CURRENCY AND PRICING 73 2.5 DBMR TRIPOD DATA VALIDATION MODEL 74 2.6 TYPE LIFELINE CURVE 78 2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 79 2.8 DBMR MARKET POSITION GRID 80 2.9 MARKET APPLICATION COVERAGE GRID 81 2.10 VENDOR SHARE ANALYSIS 82 2.11 SECONDARY SOURCES 83 2.12 ASSUMPTIONS 83 3 EXECUTIVE SUMMARY 84 4 PREMIUM INSIGHTS 86 4.1 PESTAL ANALYSIS 89 4.2 PORTERS 5 FORCES 90 4.3 EPIDEMIOLOGY 91 5 NORTH AMERICA GENETIC TESTING MARKET: REGULATIONS 92 6 MARKET OVERVIEW 94 6.1 DRIVERS 96 6.1.1 GROWING PREVALENCE OF GENETIC DISORDERS 96 6.1.2 INCREASE IN THE ADOPTION OF NEXT GENERATION SEQUENCING 96 6.1.3 WIDE PRODUCT PORTFOLIO OFFERED BY A MAJOR PLAYER 97 6.1.4 INCREASE THE TREND TOWARD PERSONALIZED MEDICATION 97 6.2 RESTRAINTS 98 6.2.1 HIGH COST OF GENETIC TESTING 98 6.2.2 CYBER SECURITY CONCERNS IN GENOMICS 99 6.3 OPPORTUNITIES 99 6.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER 99 6.3.2 TECHNOLOGICAL ADVANCEMENT IN THE FIELD OF GENETIC TESTING 100 6.3.3 INCREASING RESEARCH AND DEVELOPMENT FOR GENETIC TESTING 100 6.4 CHALLENGES 101 6.4.1 LACK OF SKILLED PROFESSIONALS TO PERFORM GENETIC TESTING 101 6.4.2 STRINGENT REGULATION POLICY FOR GENETIC TESTING 102 7 NORTH AMERICA GENETIC TESTING MARKET, BY TYPE 103 7.1 OVERVIEW 104 7.2 DIAGNOSTIC TESTING 108 7.3 PRENATAL TESTING 108 7.3.1 NON-INVASIVE SCREENING 109 7.3.1.1 WHOLE GENOME SEQUENCING 110 7.3.1.2 COUNTING OF CFDNA FRAGMENTS 110 7.3.1.3 OTHERS 110 7.3.2 BY CONDITION 111 7.3.2.1 TRISOMY 21 111 7.3.2.2 KLINEFELTER SYNDROME 111 7.3.2.3 JACOBS SYNDROME 111 7.3.2.4 CYSTIC FIBROSIS 111 7.3.2.5 TURNER SYNDROME 112 7.3.2.6 TRISOMY 18 112 7.3.2.7 HEMOPHILIA 112 7.3.2.8 TRISOMY 13 112 7.3.2.9 MICRODELETION SYNDROME 112 7.3.2.10 FETAL GENDER 112 7.3.2.11 OTHERS 112 7.3.3 BY SCREENING TYPE 113 7.3.3.1 CARRIER SEQUENCING 113 7.3.3.2 SEQUENTIAL SEQUENCING 113 7.3.4 MATERNAL SERUM QUAD SCREENING 113 7.4 NEW-BORN SCREENING 114 7.4.1 SICKLE CELL DISEASE 114 7.4.2 CONGENITAL HYPOTHYROIDISM 115 7.4.3 PHENYLKETONURINA (PKU) 115 7.4.4 GALACTOSEMIA 115 7.4.5 MAPLE SYRUP URINE DISEASE 115 7.4.6 OTHERS 115 7.5 PREDICTIVE AND PRESYMPTOMATIC TESTING 115 7.6 CARRIER TESTING 116 7.6.1 MOLECULAR SCREENING TEST 116 7.6.2 BIOCHEMICAL SCREENING TEST 117 7.6.2.1 EXPANDED CARRIER SCREENING 117 7.6.2.2 PREDESIGNED PANEL TESTING 118 7.6.2.3 CUSTOM-MADE PANEL TESTING 118 7.6.2.4 TARGETED DISEASE CARRIER SCREENING 118 7.6.2.4.1 HEMATOLOGICAL CONDITIONS 118 7.6.2.4.2 PULMONARY CONDITIONS 119 7.6.2.4.3 NEUROLOGICAL CONDITIONS 119 7.6.2.4.4 OTHER CONDITIONS 119 7.7 OTHER TYPES 119 8 NORTH AMERICA GENETIC TESTING MARKET, BY TECHNOLOGY 120 8.1 OVERVIEW 121 8.2 POLYMERASE CHAIN REACTION 124 8.2.1 REAL-TIME PCR (QPCR) 125 8.2.2 DIGITAL PCR (DPCR) 125 8.2.3 REVERSE TRANSCRIPTION PCR (RT-PCR) 125 8.2.4 HOT-START PCR 125 8.2.5 MULTIPLEX PCR 125 8.2.6 OTHER PCR 125 8.3 DNA SEQUENCING (NGS-BASED TESTING) 126 8.3.1 NEXT GENERATION SEQUENCING (NGS) 126 8.3.2 SANGER SEQUENCING (SINGLE GENE) 126 8.3.3 OTHER 127 8.4 WHOLE GENOME SEQUENCING 127 8.5 MICROARRAYS 127 8.5.1 DNA MICROARRAYS 128 8.5.2 PROTEIN MICROARRAYS 128 8.5.3 OTHER MICROARRAYS 128 8.6 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 128 8.7 OTHERS 129 9 NORTH AMERICA GENETIC TESTING MARKET, BY DISEASES 130 9.1 OVERVIEW 131 9.2 CANCER 134 9.2.1 BREAST 135 9.2.2 COLON 135 9.2.3 LUNG 135 9.2.4 PROSTATE 135 9.2.5 OTHERS 135 9.3 SICKLE CELL ANEMIA 136 9.4 THALASSEMIA 136 9.5 RARE GENETIC DISORDER 137 9.5.1 TRISOMY 21 137 9.5.2 MONOSOMY X 137 9.5.3 TRISOMY 13 138 9.5.4 MICRODELETION SYNDROME 138 9.5.5 TRISOMY 18 138 9.5.6 OTHERS 138 9.6 FRAGILE X SYNDROME 138 9.7 DUCHENNE MUSCULAR DYSTROPHY 139 9.8 HUNTINGTON'S DISEASE 139 9.9 CYSTIC FIBROSIS 140 9.10 OTHERS 140 10 NORTH AMERICA GENETIC TESTING MARKET, BY END USER 141 10.1 OVERVIEW 142 10.2 HOSPITALS 145 10.3 CLINICS 146 10.4 DIAGNOSTIC CENTERS 146 10.5 PRIVATE CLINICS 147 10.6 LABORATORY SERVICE PROVIDERS 147 10.7 PRIVATE LABORATORIES 148 11 NORTH AMERICA GENETIC TESTING MARKET, BY REGION 149 11.1 OVERVIEW 150 11.2 NORTH AMERICA 153 11.2.1 U.S 163 11.2.2 CANADA 174 11.2.3 MEXICO 185 12 NORTH AMERICA GENETIC TESTING MARKET, COMPANY LANDSCAPE 196 12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 196 13 SWOT ANALYSIS 197 14 COMPANY PROFILES 198 14.1 ILLUMINA, INC 198 14.1.1 COMPANY SNAPSHOT 198 14.1.2 REVENUE ANALYSIS 198 14.1.3 COMPANY SHARE ANALYSIS 199 14.1.4 PRODUCT PORTFOLIO 199 14.1.5 RECENT DEVELOPMENT 200 14.2 CEPHEID 201 14.2.1 COMPANY SNAPSHOT 201 14.2.2 REVENUE ANALYSIS 201 14.2.3 COMPANY SHARE ANALYSIS 202 14.2.4 PRODUCT PORTFOLIO 202 14.2.5 RECENT DEVELOPMENT 202 14.3 FULGENT GENETICS 203 14.3.1 COMPANY SNAPSHOT 203 14.3.2 REVENUE ANALYSIS 203 14.3.3 COMPANY SHARE ANALYSIS 204 14.3.4 PRODUCT PORTFOLIO 204 14.3.5 RECENT DEVELOPMENT 205 14.4 PERKINELMER INC 206 14.4.1 COMPANY SNAPSHOT 206 14.4.2 REVENUE ANALYSIS 206 14.4.3 COMPANY SHARE ANALYSIS 207 14.4.4 PRODUCT PORTFOLIO 207 14.4.5 RECENT DEVELOPMENT 207 14.5 THERMO FISHER SCIENTIFIC INC 208 14.5.1 COMPANY SNAPSHOT 208 14.5.2 REVENUE ANALYSIS 208 14.5.3 COMPANY SHARE ANALYSIS 209 14.5.4 PRODUCT PORTFOLIO 209 14.5.5 RECENT DEVELOPMENT 210 14.5.5.1 COLLABORATION 210 14.6 BIOREFERENCE 211 14.6.1 COMPANY SNAPSHOT 211 14.6.2 REVENUE ANALYSIS 211 14.6.3 PRODUCT PORTFOLIO 212 14.6.4 RECENT DEVELOPMENT 212 14.7 ELITECHGROUP 213 14.7.1 COMPANY SNAPSHOT 213 14.7.2 PRODUCT PORTFOLIO 213 14.7.3 RECENT DEVELOPMENTS 214 14.8 EUROFINS SCIENTIFIC 215 14.8.1 COMPANY SNAPSHOT 215 14.8.2 REVENUE ANALYSIS 215 14.8.3 PRODUCT PORTFOLIO 216 14.8.4 RECENT DEVELOPMENT 216 14.9 INVITAE CORPORATION 217 14.9.1 COMPANY SNAPSHOT 217 14.9.2 REVENUE ANALYSIS 217 14.9.3 PRODUCT PORTFOLIO 218 14.9.4 RECENT DEVELOPMENTS 218 14.10 MYRIAD GENETICS 219 14.10.1 COMPANY SNAPSHOT 219 14.10.2 REVENUE ANALYSIS 219 14.10.3 PRODUCT PORTFOLIO 220 14.10.4 RECENT DEVELOPMENT 220 14.11 ABBOTT 221 14.11.1 COMPANY SNAPSHOT 221 14.11.2 REVENUE ANALYSIS 221 14.11.3 PRODUCT PORTFOLIO 222 14.11.4 RECENT DEVELOPMENT 222 14.12 BIOCARTIS 223 14.12.1 COMPANY SNAPSHOT 223 14.12.2 REVENUE ANALYSIS 223 14.12.3 PRODUCT PORTFOLIO 224 14.12.4 RECENT DEVELOPMENTS 224 14.12.4.1 PARTNERSHIP 224 14.13 BIO-HELIX 225 14.13.1 COMPANY SNAPSHOT 225 14.13.2 PRODUCT PORTFOLIO 225 14.13.3 RECENT DEVELOPMENT 225 14.14 BIO-RAD LABORATORIES, INC 226 14.14.1 COMPANY SNAPSHOT 226 14.14.2 REVENUE ANALYSIS 226 14.14.3 PRODUCT PORTFOLIO 227 14.14.4 RECENT DEVELOPMENTS 227 14.15 EUGENE LABS 228 14.15.1 COMPANY SNAPSHOT 228 14.15.2 PRODUCT PORTFOLIO 228 14.15.3 RECENT DEVELOPMENT 228 14.16 F. HOFFMANN-LA ROCHE LTD 229 14.16.1 COMPANY SNAPSHOT 229 14.16.2 REVENUE ANALYSIS (PARENT COMPANY) 229 14.16.3 PRODUCT PORTFOLIO 230 14.16.4 RECENT DEVELOPMENT 230 14.17 GENES2ME 231 14.17.1 COMPANY SNAPSHOT 231 14.17.2 PRODUCT PORTFOLIO 231 14.17.3 RECENT DEVELOPMENT 231 14.18 MAPMYGENOME 232 14.18.1 COMPANY SNAPSHOT 232 14.18.2 PRODUCT PORTFOLIO 232 14.18.3 RECENT DEVELOPMENT 233 14.19 MEDGENOME 234 14.19.1 COMPANY SNAPSHOT 234 14.19.2 PRODUCT PORTFOLIO 234 14.19.3 RECENT DEVELOPMENT 235 14.20 NATERA, INC 236 14.20.1 COMPANY SNAPSHOT 236 14.20.2 REVENUE ANALYSIS 236 14.20.3 PRODUCT PORTFOLIO 237 14.20.4 RECENT DEVELOPMENT 238 14.21 OTOGENETICS 239 14.21.1 COMPANY SNAPSHOT 239 14.21.2 PRODUCT PORTFOLIO 240 14.21.3 RECENT DEVELOPMENT 240 14.22 PACBIO 241 14.22.1 COMPANY SNAPSHOT 241 14.22.2 REVENUE ANALYSIS 241 14.22.3 PRODUCT PORTFOLIO 242 14.22.4 RECENT DEVELOPMENT 242 14.23 QIAGEN 243 14.23.1 COMPANY SNAPSHOT 243 14.23.2 REVENUE ANALYSIS 243 14.23.3 PRODUCT PORTFOLIO 244 14.23.4 RECENT DEVELOPMENT 244 14.24 SORENSON GENOMICS 245 14.24.1 COMPANY SNAPSHOT 245 14.24.2 PRODUCT PORTFOLIO 245 14.24.3 RECENT DEVELOPMENT 245 15 QUESTIONNAIRE 246 16 RELATED REPORTS 249